首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1454729

免疫分析市場- 按技術（ELISA、CLIA、RIA）、產品（試劑和試劑盒、分析儀/儀器）、樣本（血液、唾液、尿液）、應用（腫瘤學、心臟病學）、最終用途（醫院和診所、診斷實驗室） ) - 全球預測，2024 - 2032

Immunoassay Market - By Technology (ELISA, CLIA, RIA), Product (Reagent & Kits, Analyzers/Instruments), Specimen (Blood, Saliva, Urine), Application (Oncology, Cardiology), End-use (Hospitals & Clinics, Diagnostic Labs) - Global Forecast, 2024 - 2032

出版日期: 2024年02月06日 | 出版商:

Global Market Insights Inc. | 英文 270 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於免疫分析技術的不斷進步和對先進診斷的強勁需求，預計 2024 年至 2032 年全球免疫分析市場規模的CAGR將達到 5.3%。隨著更靈敏、更特異的檢測等不斷創新，對複雜診斷工具的需求正在激增。最近，醫療保健提供者和患者擴大尋求針對各種疾病的準確有效的檢測方法。對診斷精度的日益成長的需求加上快速的技術進步，為免疫分析技術的擴展創造了肥沃的土壤，因為它不斷滿足不斷變化的醫療保健需求。例如，2023年7月，Fapon在2023年AACC展會期間向全球市場推出了最新的化學發光免疫分析系統Shine i8000/9000。

免疫分析產業分為技術、產品、樣本、應用、最終用途和區域。

在應用方面，受先進癌症診斷和治療監測需求不斷成長的推動，到 2032 年，腫瘤學領域的市場佔有率將顯著上升，複合CAGR為 6.2%。隨著全球癌症發生率的上升，人們更加關注早期檢測和個人化治療，其中免疫測定在提供癌症生物標記的靈敏和特異性檢測以進行及時干預方面發揮關鍵作用。隨著腫瘤學領域的不斷發展，對免疫分析技術的需求將激增，反映出對準確的癌症診斷和管理的迫切需求。

到 2032 年，免疫分析行業的診斷中心最終用途領域的CAGR將達到 6%。診斷實驗室在醫療保健領域為各種疾病提供廣泛的檢測所發揮的重要作用推動了這一成長。對準確、快速診斷工具不斷成長的需求正在加速診斷實驗室的重要性，因為它們有能力快速提供高效、可靠的結果，使它們成為醫療保健生態系統的重要組成部分。對早期疾病檢測和管理的日益關注將進一步增加對診斷實驗室的偏好。

由於醫療保健支出增加、慢性病盛行率上升以及研發活動不斷擴大，2024年至2032年亞太地區免疫分析市場規模將呈現6.1%的複合CAGR。中國和印度等國家的醫療保健產業正在顯著成長，推動了對免疫分析技術的需求。亞太地區擁有龐大的人口基數和先進的醫療基礎設施，將成為免疫分析產業擴張的重要貢獻者。

產業生態系統分析
產業影響力
- 成長動力
  - 慢性病盛行率增加
  - 免疫分析技術的進步
  - 對現場檢測的需求不斷成長
  - 提高認知和篩檢計劃
- 產業陷阱與挑戰
  - 嚴格的監管框架
  - 與免疫測定相關的挑戰
成長潛力分析
技術景觀
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
競爭定位矩陣
戰略展望矩陣

第 5 章：市場估計與預測：按產品分類，2018 年 - 2032 年

主要趨勢
試劑和試劑盒
- ELISA 試劑和試劑盒
- ELISPOT 試劑與試劑盒
- 快速檢測試劑和試劑盒
- 蛋白質印跡試劑和試劑盒
- 化學發光免疫分析試劑與試劑盒
- 免疫螢光檢測試劑及試劑盒
- 其他試劑和試劑盒
分析儀/儀器
- 開放式系統
- 封閉式系統

第 6 章：市場估計與預測：按技術分類，2018 年 - 2032 年

主要趨勢
酵素連結免疫吸附測定法 (ELISA)
化學發光免疫分析 (CLIA)
放射免疫分析（RIA）
免疫螢光分析 (IFA)
蛋白質印跡法
酵素連結免疫斑點法
其他技術

第 7 章：市場估計與預測：按樣本，2018 年 - 2032 年

主要趨勢
血
唾液
尿
其他標本

第 8 章：市場估計與預測：按應用，2018 - 2032

主要趨勢
傳染性疾病
腫瘤學
內分泌科
心臟病學
自體免疫疾病
治療藥物監測
其他應用

第 9 章：市場估計與預測：按最終用途，2018-2032 年

主要趨勢
醫院和診所
診斷中心
研究和學術實驗室
家庭護理設置
其他最終用戶

第 10 章：市場估計與預測：按地區分類，2018 年 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 11 章：公司簡介

Abbott Laboratories
Agilent Technologies, Inc.
Becton Dickinson and Company
Bio-Rad Laboratories, Inc.
Danaher Corporation
F. Hoffmann-La Roche AG
Hologic Inc.
Luminex Corporation
PerkinElmer, Inc.
QIAGEN
Sysmex Corporation
Thermo Fisher Scientific Inc.

簡介目錄

Product Code: 8041

Global Immunoassay Market size is projected to record 5.3% CAGR from 2024 to 2032 due to rising strides in immunoassay technology and the strong demand for advanced diagnostics. With ongoing innovations, such as more sensitive and specific assays, the demand for sophisticated diagnostic tools is witnessing a surge. Of late, healthcare providers and patients are increasingly seeking accurate and efficient testing methods for various diseases. This growing need for precision in diagnostics coupled with rapid technological progress is creating a fertile ground for the expansion of immunoassay techniques as it continues to cater to the evolving healthcare demands. For instance, in July 2023, Fapon introduced its newest chemiluminescence immunoassay system, the Shine i8000/9000 for the global market during the 2023 AACC exhibition.

The immunoassay industry is classified into technology, product, specimen, application, end-use, and region.

In terms of application, the market share from the oncology segment will undergo a significant upturn by depicting a 6.2% CAGR through 2032, driven by the growing demand for advanced cancer diagnostics and treatment monitoring. With cancer rate on the rise globally, there is a heightened focus on early detection and personalized therapies, where immunoassays play a pivotal role in offering sensitive and specific detection of cancer biomarkers for timely interventions. As the oncology field continues to advance, the demand for immunoassay technologies will soar, reflecting the urgent need for accurate cancer diagnostics and management.

The diagnostic centers end-use segment in the immunoassay industry will experience 6% CAGR up to 2032. This is fueled by the essential role diagnostic labs play in healthcare for offering a wide array of tests for various diseases. The growing demand for accurate and rapid diagnostic tools is accelerating the significance of diagnostic labs as they have the ability to provide efficient and reliable results swiftly, making them a vital component in the healthcare ecosystem. The rising focus on early disease detection and management will further augment the preference for diagnostic labs.

Asia Pacific immunoassay market size will demonstrate a 6.1% CAGR from 2024 to 2032, attributed to the increasing healthcare expenditure, rising prevalence of chronic diseases, and expanding R&D activities. Countries like China and India are witnessing significant growth in the healthcare sector, propelling the demand for immunoassay technologies. With a vast population base and advancing healthcare infrastructure, Asia Pacific will emerge as a significant contributor to the immunoassay industry expansion.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increase in the prevalence of chronic conditions
  - 3.2.1.2 Advancements in immunoassay technologies
  - 3.2.1.3 Growing demand for point-of-care testing
  - 3.2.1.4 Rising awareness and screening programs
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory framework
  - 3.2.2.2 Challenges associated with immunoassay
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
- 3.6.1 Supplier power
- 3.6.2 Buyer power
- 3.6.3 Threat of new entrants
- 3.6.4 Threat of substitutes
- 3.6.5 Industry rivalry
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Reagents & kits
- 5.2.1 ELISA reagents & kits
- 5.2.2 ELISPOT reagents & kits
- 5.2.3 Rapid test reagents & kits
- 5.2.4 Western blot reagents & kits
- 5.2.5 Chemiluminescence immunoassay reagents & kits
- 5.2.6 Immunofluorescence assay reagents & kits
- 5.2.7 Other reagents & kits
5.3 Analyzers/Instruments
- 5.3.1 Open ended systems
- 5.3.2 Closed ended systems

Chapter 6 Market Estimates and Forecast, By Technology, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Enzyme-linked immunosorbent assay (ELISA)
6.3 Chemiluminescence immunoassay (CLIA)
6.4 Radioimmunoassay (RIA)
6.5 Immunofluorescence assay (IFA)
6.6 Western blotting
6.7 ELISpot
6.8 Other technologies

Chapter 7 Market Estimates and Forecast, By Specimen, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Blood
7.3 Saliva
7.4 Urine
7.5 Other specimens

Chapter 8 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Infectious diseases
8.3 Oncology
8.4 Endocrinology
8.5 Cardiology
8.6 Autoimmune diseases
8.7 Therapeutic drug monitoring
8.8 Other applications

Chapter 9 Market Estimates and Forecast, By End-Use, 2018-2032 ($ Mn)

9.1 Key trends
9.2 Hospitals and clinics
9.3 Diagnostic centers
9.4 Research and academic laboratories
9.5 Homecare settings
9.6 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa